Founder, Chairman & CEO
Robert DiCrisci is the Founder and CEO of
NextSource Biotechnology (NSB), a sister company of Amatheon Pharmaceuticals. Mr. DiCrisci
has over 18 years of experience in the healthcare and pharmaceuticals industry. He began his career being recruited by Microsoft
while still in his second year of college, immediately rising to become one of their top field consultants working on projects at
the C-level in organizations like Cosabella Inc., Health Coalition, University of Michigan Health Systems, AAA Auto Club Group, HRH
Construction and Sirco Associates.
Before founding Amatheon, Mr. DiCrisci served as Executive Director of Medical Staffing Network (MSN), which was the largest
publicly traded medical staffing firm in the U.S., with revenues of more than $500 million. After leaving MSN, he founded Amatheon
Pharmaceuticals and spent over 13 years building it into the leading distributor of hard-to-find human drugs for the veterinary
market. His decade plus of experience in dealing with the difficulties of vet practitioners face with various short supply human
drugs is what prompted him to found NextSource, which is dedicated to consolidating human-to-vet “Cross-Over” medications (and
their supply chains) for the benefit of the veterinary market.
Mr. DiCrisci graduated Summa Cum Laude from the University of Central Florida, with a Bachelor of Business Administration (BBA) in
Finance, Marketing & Computer Science as well as attending Harvard Business School (HSB) earning his MBA in Management / Finance
and with Honors. He has been a Microsoft Certified Systems Engineer (MCSE) since 1998 and he has been the Licensed DEA Registrant
in the Pharmaceutical industry for over 10 years.
Prior to joining NextSource, Mr. Osman founded Osman Page in 2005,
Mr. Osman spent the majority of his career as the Director of
Financial Operations for a $500 MM publicly traded healthcare company, Medical Staffing Network, located in Boca Raton, FL. During
his tenure with MSN, Mohamed was instrumental in completing the acquisition of over 30 companies, opening more than 300 locations
across the country, and growing the company to 700 plus employees and 20,000 Temporary Nurses within a five-year period. This
period of growth resulted in a private equity raise of $185 MM from the global investment firm of Warburg Pincus along with the
acquisition of a $120 MM debt facility in 2001. In 2002, the work of the senior management team culminated in an Initial Public
Offering (IPO) of $170.6 MM.
Mr. Osman brings more than 20 years of business experience in Accounting & IT to NextSource. He holds a B.S. degree in Accounting
along with an MBA in Technology Management. In addition, Mr. Osman is a CISA (Certified Information Systems Auditor).
Chris F. Yankana
Chief Financial Officer
Chris Yankana is the Chief Financial Officer (CFO) of
NextSource Biotechnology (NSB). Mr. Yankana has over 20 years of experience in the healthcare
and pharmaceutical industry as CFO, Controller, Auditor and Sales Manager. As the CFO for NextSource, he plays a vital role in
developing and implementing the national strategies, financial planning, purchasing programs. He also serves as an advisor to all
department including the Sales/Marketing initiatives. He is responsible for overseeing all fiscal and fiduciary responsibilities
for NextSource Biotechnology and its subsidiaries.
Mr. Yankana is the Resident Certified Designated Representative and is also a Certified Public Accountant (CPA). His experience
includes positions as the Controller then Sales Manager for Health Coalition; prior to this he served as an Accounting Auditor
for several large NYC companies.
Kevin A. Hahn, DVM, PHD, DACVIM
Chief Scientific Officer, Executive Vice President
Kevin A. Hahn, DVM, PhD, DACVIM (Oncology) is Chief Scientific Officer
(CSO) and Executive Vice President for NextSource Biotechnology (NSB).
Dr. Hahn has over 25 years of experience in the veterinary healthcare, nutrition, and pharmaceutical industry. As CSO he leads the
NextSource Biotechnology global new product pre-clinical development and regulatory approval strategy and serves as a key advisor
during the development and implementation of Sales/Marketing initiatives.
Prior to joining NextSource Biotechnology he served as Chief Medical Officer for Hill’s Pet Nutrition, Inc. (Topeka, KS); Senior
Partner for Gulf Coast Veterinary Oncology & Diagnostic Imaging (Houston, TX); and Associate Professor of Medical Oncology,
University of Tennessee (Knoxville, TN).
Dr. Hahn is an entrepreneur, scientist, veterinarian, and community supporter. He actively participates in causes that enrich the
human-animal bond as well as the human-spiritual bond. He is recognized internationally in the discipline of veterinary medical
oncology, companion animal nutrition, comparative biosciences, and is an active leader in the animal health industry.
Richard C. Dinovitz
Chief Commercial Officer & Executive Vice President
Richard Dinovitz is Chief Commercial Officer (CCO) and
Executive Vice President for NextSource Biotechnology (NSB).
Richard has over 35 years of experience in the vaccine, biological, biotech, and pharmaceutical industries. As CCO he is
responsible for the NextSource Biotechnology global strategy and the development of the organization to drive business growth and
Richard is an accomplished sales and marketing officer-level executive with wide-ranging experience in complex technical markets.
He is a creative thinker equally comfortable in strategic planning, business development product launches, commercial team
management and leadership. He is a serial entrepreneur experienced in company startups, venture funding, co-promotions, mergers and
acquisitions. Richard is a business executive who understands the need to exceed expectations as well as to over achieve aggressive
Richard spent over 30 years in positions of increasing responsibility with Pfizer where he consistently delivered strong financial
growth through building high performing teams, identifying/capitalizing on business and product specification opportunities,
expanding distribution channels/networks, launching new products, and developing innovative marketing strategies. Additionally, he
gained considerable expertise in government negotiation, commercial operations, strategic alliance management, and contracting.
As Vice President, Business Development at a start-up company, Nuron Biotech, Richard impressively led the company's effort to
acquire five pharmaceutical and vaccine products within a two year period. He successfully worked with investors to secure
sufficient capital to ensure appropriate funding of the company.
Richard received his B.S degree from the University of Pittsburgh. Richard remains active in various Trade Organizations and